

# 04821 The evolution of carbapenem resistance determinants and major

epidemiological lineages among carbapenem-resistant Acinetobacter baumannii

## isolates in Germany, 2010-2019

### 03. Bacterial susceptibility & resistance

<u>E. Wohlfarth <sup>1</sup></u>, M. Kresken <sup>1, 2</sup>, P. Higgins <sup>3, 4</sup>, D. Stefanik <sup>3</sup>, J. Wille <sup>3, 4</sup>, B. Körber-Irrgang <sup>1, 5</sup>, H. Seifert <sup>3, 4</sup>

<sup>1</sup>Antiinfectives Intelligence GmbH, c/o Rechtsrheinisches Technologie- und Gründerzentrum, Gottfried-Hagen-Straße 60-62, 51105 Cologne - Cologne (Germany), <sup>2</sup>University of Applied Sciences, Schaevenstr. 1 a-b, 50676 Cologne - Cologne (Germany), <sup>3</sup>Institute for Medical Microbiology, Immunology and Hygiene, Goldenfelsstr. 19-21, 50935 Cologne - Cologne (Germany), <sup>4</sup>German Center for Infection Research (DZIF), Partner-Site Bonn-Cologne (Germany), <sup>5</sup>Merlin Diagnostika GmbH, Kleinstraße 14, 53332 Bornheim - Bornheim (Germany)

#### Background

Acinetobacter baumannii is a major pathogen causing healthcare-associated infections, especially in intensive care units (ICU). While carbapenems play an important role in the treatment of *A. baumannii* infections, the species can develop carbapenem resistance due to overexpression of the intrinsic class D  $\beta$ -lactamase gene *bla*<sub>OXA-51-like</sub> or presence of acquired genes including *bla*<sub>OXA-23-like</sub>, *bla*<sub>OXA-40-like</sub> and *bla*<sub>OXA-58-like</sub>. The objectives of this study were i) to evaluate the occurrence of carbapenem resistance determinants among *A. baumannii* isolates collected during four multicentre surveillance studies conducted by the Paul-Ehrlich-Society between 2010 and 2019, and ii) to investigate the molecular epidemiology of these isolates.

#### **Methods**

Isolates were collected prospectively from hospitalised patients at 17 medical centres in Germany, in each case over a three-month-period in the years 2010, 2013 2016 and 2019. Verification of species identification and susceptibility testing were performed in a reference laboratory. MICs were determined by broth microdilution (ISO-standard) and interpreted by EUCAST breakpoints (v.11.0). The prevalence of *bla*<sub>OXA</sub> genes was investigated by oxacillinase (OXA)-multiplex PCR and wholegenome sequencing. The molecular epidemiology was examined by repetitive sequence-based PCR (rep-PCR; DiversiLab) and core-genome MLST.

### Results

Overall, 302 *A. baumannii* isolates were collected, including 72 ICU isolates and 230 non-ICU isolates. Resistance to imipenem and/or meropenem was detected in 58 isolates (Table 1). The proportion of resistant isolates evolved from 16/75 (21.3%) in 2010 to 20/60 (33.3%) in 2013 and then decreased to 13/94 (13.8%) in 2016 and 9/73 (12.3%) in 2019 (chi-squared trend analysis, p < 0.05). Forty-six carbapenem-resistant isolates (79.3%) were associated with the clonal lineage IC 2 and five (8.6%) with IC 1 (Table 2). The majority of resistant isolates (87.9%) encoded *bla*OXA-23-like (Table 3). Other carbapenem-resistance determinants detected were OXA-40-like (n=1), OXA-58-like (n=3), overexpression of OXA-51-like (n=1) and NDM-1 (n=2).

## Conclusions

This nationwide study found a pooled rate of non-susceptibility to carbapenems in *A. baumannii* of 19.2% (95%-CI: 14.8-23.6%) in the period 2010-2019. Interestingly, a decrease in carbapenem-resistant isolates was detected from 2013 onwards, which seems to indicate a reduction of carbapenem resistance in this species in Germany.

#### Table 1

Centre	Year of isolation								
	2010		2013		2016		2019		No. of CR isolates
	No. collected	No. CR	No. collected	No. CR	No. collected	No. CR	No. collected	No. CR	2010-2019
306	5	-	2	-	2	-	2		-
309	1	-	2	1	6	-	2	-	1
312	10	-	1	-	9	-	4	2	2
317	1	-	-	-	2	1	1		1
318	2	1	8	6	2	-	7	2	9
319	6	-	4		6	3	9	-	3
321	1	-	4	-	4	-	-	-	-
322	1	-	3		10	1	10		1
323	5	1	1	1	6	3	4	-	5
324	6	1	5		5	2	4		3
325	11	3	8	3	5	1	6	-	7
326	7	2	6	5	5	-	7	2	9
352	1	1	5	-	9	-	7	1	2
353	11	5	4	3	2	1	4	2	11
355	-	-		-	12	-	2	-	-
356	5	1	4	-	2	-	3	-	1
357	2	1	3	1	7	1	1		3
Total	75	16	60	20	94	13	73	9	58
% CR		21.3		33.3		13.8		12.3	19.2

# Table 2

Statistics and	Year of isolation					
Clonal lineage	2010	2013	2013 2016		Total	
IC-1		1	4		5	
IC-2	14	18	6	8	46	
IC-4	1				1	
IC-7			1		1	
No IC	1	1	2	1	5	
Total	16	20	13	9	58	

Table 2: International clonal (IC) lineages associated with carbapenem-resistant <u>A. baumannii</u> (n=58) by year of isolation

# Table 3

Table 3: Prevalence of acquired CP genes by year of isolation

Clonal lineage	CP gene	2010	2013	2016	2019	Total
IC-1	OXA-23-like		1	4		5
IG-2	OXA-23-like	13	16	6	8	43
	OXA-40-like		1			1
	OXA-58-like	1	1			2
IC-4	Overexpression of OXA-51-like	1				1
IC-7	OXA-23-like			1		1
No IC	OXA-23-like	1		1		2
	NDM-1		1	1		2
	OXA-58-like				1	1
Total		16	20	13	9	58